Oral Zepbound and Wegovy: A New Era in Weight Loss Medications

For years, individuals seeking weight loss assistance have relied on injectable GLP-1 medications like Zepbound and Wegovy. Now, a new option is available: an oral formulation of these drugs, offering a potentially more accessible and convenient approach to weight management. This development could significantly impact how obesity is treated, making medications more readily available to a wider range of patients.

The Shift from Injections to Pills

Previously, GLP-1 medications for weight loss were exclusively available as injections. The recent release of a pill version, particularly of Wegovy, marks a significant change. Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, highlights the advantages of this shift: “It’s very, very exciting. The thing that’s so essential about it is that it’s going to be less expensive. It’s easier to distribute.”

Accessibility and Cost Considerations

The oral formulation addresses several barriers to treatment. Injections require refrigeration, which can be a logistical challenge for some patients. Dr. Aronne anticipates that the pill form will be more popular due to its convenience and potential for lower cost. “When you think about other chronic diseases, high blood pressure, high cholesterol, what we found is that the earlier you treat people, the easier it is to treat. The better result you’ll receive. So, what I envision is going to happen is that people are going to be seen earlier and treated earlier,” he stated.

Impact on Insurance Coverage

A major hurdle in accessing GLP-1 medications has been insurance coverage. Insurance companies have often been reluctant to cover these medications due to their cost. Dr. Aronne believes that the availability of oral medications may change this. “The biggest barrier we have right now is a lack of insurance coverage. Insurance companies don’t want to cover these medications, but I think that there is a possibility that now that we have oral medicines available, they will be willing to cover it,” he explained.

How the Medications Work

Both Zepbound (tirzepatide) and Wegovy (semaglutide) work by mimicking hormones that regulate appetite and fullness. Zepbound targets two hormones – GLP-1 and GIP – while Wegovy targets only GLP-1. Dr. Aronne emphasizes that the oral pill will have a similar impact on weight loss as the injection. “I believe this is going to be a major advance in treating people who have weight problems and the reason is it’s going to be more accessible. It’s going to be less expensive. There’s no injection, which deters a lot of people. Side effect-wise, it’s the same. There’s really no difference,” he said.

Dosage and Administration

While the injectable Zepbound is administered weekly, the oral medication will be taken daily, specifically on an empty stomach 30 minutes before eating. Another version of the pill is expected to be released later this year.

Potential Side Effects

Like all medications, Wegovy and Zepbound have potential side effects, including gallbladder issues, risk of low blood sugar, and stomach problems. Clinical trials have shown that approximately 6% of Zepbound users and 8% of Wegovy users discontinued treatment due to side effects. Weill Cornell Medicine

Key Takeaways

• Oral formulations of GLP-1 medications like Wegovy are now available.
• The pill form offers increased accessibility and convenience compared to injections.
• Insurance coverage may improve with the availability of oral medications.
• The oral medication is taken daily on an empty stomach 30 minutes before eating.
• Side effects are similar to those associated with the injectable versions.